For more than 20 years, Illumina has aspired to improve human health by unlocking the power of the genome. Now, through innovation and collaboration with pathologists, hematologists, and oncologists, we are enabling genomic breakthroughs in immunotherapy, biomarker discovery, and therapy selection. As we move towards precision medicine, we have only just begun to discover the true impact of genomics. The opportunity to transform tumor profiling with innovative assays that enable comprehensive genomic profiling, new companion diagnostic development, and liquid biopsy inspires us to push boundaries and drive innovation.